Open AccessHeterogeneous magnitude of immunological memory to SARS‐CoV‐2 in recovered individuals
Author(s) -
Mazzoni Alessio,
Maggi Laura,
Capone Manuela,
Vanni Anna,
Spinicci Michele,
Salvati Lorenzo,
Tekle Kiros Seble,
Semeraro Roberto,
Pengue Luca,
Colao Maria Grazia,
Magi Alberto,
Rossolini Gian Maria,
Liotta Francesco,
Cosmi Lorenzo,
Bartoloni Alessandro,
Annunziato Francesco
Publication year - 2021
Publication title -
clinical and translational immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.321
H-Index - 34
ISSN - 2050-0068
DOI - 10.1002/cti2.1281
Subject(s) - immunology , asymptomatic , immune system , humoral immunity , acquired immune system , antibody , vaccination , immunity , disease , biology , covid-19 , medicine , virology , infectious disease (medical specialty)
Objective Although the adaptive immune response to SARS‐CoV‐2 has been characterised in the acute and early convalescent phase of the disease, few studies explore whether natural infection elicits long‐lasting immunological memory in recovered individuals. In this work, we aimed to assess the maintenance of immunological memory to SARS‐CoV‐2. Methods We evaluated the long‐term virus‐specific cellular and humoral immune response in the members of an Italian Serie A football team, who experienced a cluster of COVID‐19 in March 2020, which was strictly evaluated in the following months. Results Our results highlight a heterogeneous magnitude of immunological memory at 5 months after infection. Indeed, 20% of the subjects displayed a weak cellular and humoral memory to SARS‐CoV‐2, suggesting that they may be at higher risk of reinfection. In addition, a history of symptomatic COVID‐19 was associated with higher levels of SARS‐CoV‐2‐reactive CD4 + T cells and specific antibody levels than in asymptomatic individuals. Conclusion Collectively, these data demonstrate that immunity to SARS‐CoV‐2 is maintained five months postinfection even if the magnitude of response is heterogeneous among individuals. This finding suggests that some COVID‐19‐recovered subjects may benefit from vaccination.